{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T07:43:25Z","timestamp":1788507805151,"version":"build-2803163510"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T00:00:00Z","timestamp":1769817600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T00:00:00Z","timestamp":1769817600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurosurg Rev"],"DOI":"10.1007\/s10143-025-04097-6","type":"journal-article","created":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T04:58:54Z","timestamp":1769835534000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Radiation therapy combined with tyrosine kinase inhibitors in 826 patients with HER2-positive breast cancer brain metastases: a systematic review and network meta-analysis"],"prefix":"10.1007","volume":"49","author":[{"given":"Amirhossein","family":"Zare","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza Soltani","family":"Khaboushan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Mohammadzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Mortezaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirhessam","family":"Zare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bardia","family":"Hajikarimloo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Ghalehtaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven D.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,31]]},"reference":[{"issue":"5","key":"4097_CR1","first-page":"355","volume":"70","author":"GM Choong","year":"2020","unstructured":"Choong GM, Cullen GD, O\u2019Sullivan CC (2020) Evolving standards of care and new challenges in the management of HER2-positive breast cancer. CA Cancer J Clin 70(5):355\u2013374","journal-title":"CA Cancer J Clin"},{"issue":"4905","key":"4097_CR2","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1126\/science.2470152","volume":"244","author":"DJ Slamon","year":"1989","unstructured":"Slamon DJ et al (1989) Studies of the HER-2\/neu proto-oncogene in human breast and ovarian cancer. Science 244(4905):707\u2013712","journal-title":"Science"},{"issue":"3","key":"4097_CR3","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209\u2013249","journal-title":"CA Cancer J Clin"},{"issue":"10","key":"4097_CR4","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1200\/OP.21.00172","volume":"17","author":"O Mart\u00ednez-S\u00e1ez","year":"2021","unstructured":"Mart\u00ednez-S\u00e1ez O, Prat A (2021) Current and future management of HER2-positive metastatic breast cancer. JCO Oncol Pract 17(10):594\u2013604","journal-title":"JCO Oncol Pract"},{"issue":"36","key":"4097_CR5","doi-asserted-by":"publisher","first-page":"5658","DOI":"10.1200\/JCO.2006.07.0250","volume":"24","author":"Z Gabos","year":"2006","unstructured":"Gabos Z et al (2006) Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer. J Clin Oncol 24(36):5658\u20135663","journal-title":"J Clin Oncol"},{"issue":"8","key":"4097_CR6","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1001\/jamaoncol.2017.0001","volume":"3","author":"AM Martin","year":"2017","unstructured":"Martin AM et al (2017) Brain metastases in newly diagnosed breast cancer: A Population-Based study. JAMA Oncol 3(8):1069\u20131077","journal-title":"JAMA Oncol"},{"issue":"12","key":"4097_CR7","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1093\/annonc\/mdz410","volume":"30","author":"M Lange","year":"2019","unstructured":"Lange M et al (2019) Cancer-related cognitive impairment: an update on state of the art, detection, and management strategies in cancer survivors. Ann Oncol 30(12):1925\u20131940","journal-title":"Ann Oncol"},{"key":"4097_CR8","doi-asserted-by":"publisher","first-page":"469580211055636","DOI":"10.1177\/00469580211055636","volume":"58","author":"DJ He","year":"2021","unstructured":"He DJ et al (2021) Breast cancer subtypes and mortality of breast cancer patients with brain metastasis at diagnosis: A Population-Based study. Inquiry 58:469580211055636","journal-title":"Inquiry"},{"issue":"5","key":"4097_CR9","doi-asserted-by":"publisher","first-page":"412","DOI":"10.5001\/omj.2019.76","volume":"34","author":"KF Zahid","year":"2019","unstructured":"Zahid KF et al (2019) Outcome of Omani women with breast Cancer-associated brain metastases experience from a university hospital. Oman Med J 34(5):412\u2013419","journal-title":"Oman Med J"},{"issue":"5","key":"4097_CR10","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1200\/JCO.21.02314","volume":"40","author":"MA Vogelbaum","year":"2022","unstructured":"Vogelbaum MA et al (2022) Treatment for brain metastases: ASCO-SNO-ASTRO guideline. J Clin Oncol 40(5):492\u2013516","journal-title":"J Clin Oncol"},{"issue":"7","key":"4097_CR11","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.clon.2020.02.001","volume":"32","author":"S Raman","year":"2020","unstructured":"Raman S et al (2020) Whole brain radiotherapy versus stereotactic radiosurgery in Poor-Prognosis patients with one to 10 brain metastases: A randomised feasibility study. Clin Oncol (R Coll Radiol) 32(7):442\u2013451","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"22","key":"4097_CR12","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.21037\/atm-22-5352","volume":"10","author":"J Chen","year":"2022","unstructured":"Chen J et al (2022) Efficacy and safety of Pyrotinib and radiotherapy vs. Pyrotinib-based therapy in patients with HER2(+) breast cancer with brain metastasis: a retrospective cohort study. Ann Transl Med 10(22):1228","journal-title":"Ann Transl Med"},{"issue":"2","key":"4097_CR13","doi-asserted-by":"publisher","first-page":"417","DOI":"10.4143\/crt.2021.575","volume":"54","author":"OO Akagunduz","year":"2022","unstructured":"Akagunduz OO et al (2022) Radiation-Induced ocular surface disorders and retinopathy: ocular structures and radiation Dose-Volume effect. Cancer Res Treat 54(2):417\u2013423","journal-title":"Cancer Res Treat"},{"issue":"12","key":"4097_CR14","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.6004\/jnccn.2017.7003","volume":"15","author":"BH Kann","year":"2017","unstructured":"Kann BH et al (2017) Radiosurgery for brain metastases: changing practice patterns and disparities in the united States. J Natl Compr Canc Netw 15(12):1494\u20131502","journal-title":"J Natl Compr Canc Netw"},{"key":"4097_CR15","doi-asserted-by":"crossref","unstructured":"Balduzzi S et al (2014) Trastuzumab-containing regimens for metastatic breast cancer. Cochrane Database Syst Rev 2014(6):Cd006242","DOI":"10.1002\/14651858.CD006242.pub2"},{"issue":"4","key":"4097_CR16","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/sj.bjc.6601970","volume":"91","author":"AJ Clayton","year":"2004","unstructured":"Clayton AJ et al (2004) Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer 91(4):639\u2013643","journal-title":"Br J Cancer"},{"issue":"14","key":"4097_CR17","doi-asserted-by":"publisher","first-page":"3529","DOI":"10.1158\/1078-0432.CCR-16-1496","volume":"23","author":"SL Moulder","year":"2017","unstructured":"Moulder SL et al (2017) Phase I study of ONT-380, a HER2 Inhibitor, in patients with HER2(+)-Advanced solid Tumors, with an expansion cohort in HER2(+) metastatic breast cancer (MBC). Clin Cancer Res 23(14):3529\u20133536","journal-title":"Clin Cancer Res"},{"issue":"14","key":"4097_CR18","doi-asserted-by":"publisher","first-page":"15090","DOI":"10.1002\/cam4.6180","volume":"12","author":"Y Yu","year":"2023","unstructured":"Yu Y et al (2023) Tyrosine kinase inhibitors in HER2-positive breast cancer brain metastases: A systematic review and meta-analysis. Cancer Med 12(14):15090\u201315100","journal-title":"Cancer Med"},{"key":"4097_CR19","doi-asserted-by":"publisher","first-page":"107327482210992","DOI":"10.1177\/10732748221099230","volume":"29","author":"J Xie","year":"2022","unstructured":"Xie J et al (2022) Therapeutic landscape of human epidermal growth factor receptor 2-Positive breast cancer. Cancer Control 29:10732748221099230","journal-title":"Cancer Control"},{"issue":"3","key":"4097_CR20","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/S1470-2045(21)00716-6","volume":"23","author":"M Yan","year":"2022","unstructured":"Yan M et al (2022) Pyrotinib plus capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases (PERMEATE): a multicentre, single-arm, two-cohort, phase 2 trial. Lancet Oncol 23(3):353\u2013361","journal-title":"Lancet Oncol"},{"issue":"6","key":"4097_CR21","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.21037\/tcr-23-333","volume":"12","author":"I Kioutchoukova","year":"2023","unstructured":"Kioutchoukova I, Lucke-Wold BP (2023) Pyrotinib as a therapeutic for HER2-positive breast cancer. Transl Cancer Res 12(6):1376\u20131379","journal-title":"Transl Cancer Res"},{"issue":"1","key":"4097_CR22","doi-asserted-by":"publisher","first-page":"e622","DOI":"10.1097\/CAD.0000000000001199","volume":"33","author":"W Tian","year":"2022","unstructured":"Tian W et al (2022) Pyrotinib treatment enhances the radiosensitivity in HER2-positive brain metastatic breast cancer patients. Anticancer Drugs 33(1):e622\u2013e627","journal-title":"Anticancer Drugs"},{"issue":"2","key":"4097_CR23","doi-asserted-by":"publisher","first-page":"503","DOI":"10.3171\/2018.10.JNS182340","volume":"132","author":"S Parsai","year":"2020","unstructured":"Parsai S et al (2020) Stereotactic radiosurgery with concurrent lapatinib is associated with improved local control for HER2-positive breast cancer brain metastases. J Neurosurg 132(2):503\u2013511","journal-title":"J Neurosurg"},{"key":"4097_CR24","first-page":"841","volume":"15","author":"J Huang","year":"2023","unstructured":"Huang J et al (2023) Efficacy and safety of radiotherapy combined with Pyrotinib in the treatment of HER2-Positive breast cancer with brain metastases. Breast Cancer (Dove Med Press) 15:841\u2013853","journal-title":"Breast Cancer (Dove Med Press)"},{"issue":"1","key":"4097_CR25","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/s41416-020-01175-y","volume":"124","author":"C Bailleux","year":"2021","unstructured":"Bailleux C, Eberst L, Bachelot T (2021) Treatment strategies for breast cancer brain metastases. Br J Cancer 124(1):142\u2013155","journal-title":"Br J Cancer"},{"issue":"11","key":"4097_CR26","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B et al (2015) The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 162(11):777\u2013784","journal-title":"Ann Intern Med"},{"key":"4097_CR27","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JAC Sterne","year":"2016","unstructured":"Sterne JAC et al (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 355:i4919","journal-title":"BMJ"},{"key":"4097_CR28","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP et al (2011) The Cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ 343:d5928","journal-title":"BMJ"},{"issue":"1","key":"4097_CR29","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/jrsm.1411","volume":"12","author":"LA McGuinness","year":"2021","unstructured":"McGuinness LA, Higgins JPT (2021) Risk-of-bias visualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments. Res Synth Methods 12(1):55\u201361","journal-title":"Res Synth Methods"},{"key":"4097_CR30","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1471-2288-12-9","volume":"12","author":"P Guyot","year":"2012","unstructured":"Guyot P et al (2012) Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol 12:9","journal-title":"BMC Med Res Methodol"},{"issue":"3","key":"4097_CR31","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1002\/cam4.4481","volume":"11","author":"M Gao","year":"2022","unstructured":"Gao M et al (2022) The efficacy and safety of Pyrotinib in treating HER2-positive breast cancer patients with brain metastasis: A multicenter study. Cancer Med 11(3):735\u2013742","journal-title":"Cancer Med"},{"issue":"23","key":"4097_CR32","doi-asserted-by":"publisher","first-page":"8352","DOI":"10.1002\/cam4.4335","volume":"10","author":"C Li","year":"2021","unstructured":"Li C et al (2021) Effectiveness and safety of pyrotinib-based therapy in patients with HER2-positive metastatic breast cancer: A real-world retrospective study. Cancer Med 10(23):8352\u20138364","journal-title":"Cancer Med"},{"issue":"2","key":"4097_CR33","doi-asserted-by":"publisher","first-page":"e198","DOI":"10.1093\/oncolo\/oyad228","volume":"29","author":"X Liang","year":"2024","unstructured":"Liang X et al (2024) Long-term outcome analysis of Pyrotinib in patients with HER2-Positive metastatic breast cancer and brain metastasis: A Real-World study. Oncologist 29(2):e198\u2013e205","journal-title":"Oncologist"},{"key":"4097_CR34","doi-asserted-by":"publisher","first-page":"101029","DOI":"10.1016\/j.neo.2024.101029","volume":"56","author":"L Dai","year":"2024","unstructured":"Dai L et al (2024) Efficacy and safety of pyrotinib-based regimens in HER2 positive metastatic breast cancer: A retrospective real-world data study. Neoplasia 56:101029","journal-title":"Neoplasia"},{"issue":"6","key":"4097_CR35","doi-asserted-by":"publisher","first-page":"e509","DOI":"10.1016\/j.clbc.2024.04.001","volume":"24","author":"J Huang","year":"2024","unstructured":"Huang J et al (2024) Effectiveness and safety of pyrotinib-based therapy in the treatment of HER2-positive breast cancer patients with brain metastases: a multicenter real-world study. Clin Breast Cancer 24(6):e509\u2013e518 e1","journal-title":"Clin Breast Cancer"},{"issue":"5","key":"4097_CR36","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1016\/j.ijrobp.2023.07.019","volume":"118","author":"IA Kim","year":"2024","unstructured":"Kim IA et al (2024) Concurrent lapatinib with brain radiation therapy in patients with HER2\u2009+\u2009Breast cancer with brain metastases: NRG Oncology-KROG\/RTOG 1119 phase 2 randomized trial. Int J Radiat Oncol Biol Phys 118(5):1391\u20131401","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"4097_CR37","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1093\/neuonc\/noz006","volume":"21","author":"JM Kim","year":"2019","unstructured":"Kim JM et al (2019) Stereotactic radiosurgery with concurrent HER2-directed therapy is associated with improved objective response for breast cancer brain metastasis. Neuro Oncol 21(5):659\u2013668","journal-title":"Neuro Oncol"},{"issue":"5","key":"4097_CR38","doi-asserted-by":"publisher","first-page":"100256","DOI":"10.1016\/j.esmoop.2021.100256","volume":"6","author":"E Stavrou","year":"2021","unstructured":"Stavrou E, Winer EP, Lin NU (2021) How we treat HER2-positive brain metastases. ESMO Open 6(5):100256","journal-title":"ESMO Open"},{"issue":"2","key":"4097_CR39","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1177\/15353702221142605","volume":"248","author":"X Ma","year":"2023","unstructured":"Ma X et al (2023) Pyrotinib combining with radiotherapy on breast cancer with brain metastasis. Exp Biol Med (Maywood) 248(2):106\u2013116","journal-title":"Exp Biol Med (Maywood)"},{"issue":"24","key":"4097_CR40","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.4161\/cbt.8.24.10131","volume":"8","author":"M No","year":"2009","unstructured":"No M, Jung CE, and I.A. and, Kim (2009) Targeting HER2 signaling pathway for radiosensitization: alternative strategy for therapeutic resistance. Cancer Biol Ther 8(24):2351\u20132361","journal-title":"Cancer Biol Ther"},{"issue":"1\u20132","key":"4097_CR41","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1159\/000528594","volume":"46","author":"Q Niu","year":"2023","unstructured":"Niu Q et al (2023) Pan-HER tyrosine kinase inhibitor Pyrotinib enhances radiosensitivity via ERK1\/2 pathway in HER2-positive gastric cancer. Oncol Res Treat 46(1\u20132):11\u201325","journal-title":"Oncol Res Treat"},{"key":"4097_CR42","doi-asserted-by":"publisher","first-page":"104185","DOI":"10.1016\/j.critrevonc.2023.104185","volume":"192","author":"G Giordano","year":"2023","unstructured":"Giordano G et al (2023) Multidisciplinary management of HER2-positive breast cancer with brain metastases: an evidence-based pragmatic approach moving from pathophysiology to clinical data. Crit Rev Oncol Hematol 192:104185","journal-title":"Crit Rev Oncol Hematol"},{"issue":"4","key":"4097_CR43","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1200\/JCO.2011.38.0527","volume":"30","author":"PW Sperduto","year":"2012","unstructured":"Sperduto PW et al (2012) Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol 30(4):419\u2013425","journal-title":"J Clin Oncol"},{"issue":"4","key":"4097_CR44","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S1470-2045(19)30863-0","volume":"21","author":"SM Swain","year":"2020","unstructured":"Swain SM et al (2020) Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol 21(4):519\u2013530","journal-title":"Lancet Oncol"},{"issue":"3","key":"4097_CR45","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1001\/jamaoncol.2023.5791","volume":"10","author":"Z Yang","year":"2024","unstructured":"Yang Z et al (2024) Brain radiotherapy with Pyrotinib and capecitabine in patients with ERBB2-Positive advanced breast cancer and brain metastases: A nonrandomized phase 2 trial. JAMA Oncol 10(3):335\u2013341","journal-title":"JAMA Oncol"},{"issue":"3","key":"4097_CR46","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/S1470-2045(20)30702-6","volume":"22","author":"B Xu","year":"2021","unstructured":"Xu B et al (2021) Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol 22(3):351\u2013360","journal-title":"Lancet Oncol"},{"issue":"29","key":"4097_CR47","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1200\/JCO.19.00108","volume":"37","author":"F Ma","year":"2019","unstructured":"Ma F et al (2019) Pyrotinib or lapatinib combined with capecitabine in HER2-Positive metastatic breast cancer with prior Taxanes, Anthracyclines, and\/or trastuzumab: A Randomized, phase II study. J Clin Oncol 37(29):2610\u20132619","journal-title":"J Clin Oncol"},{"issue":"4","key":"4097_CR48","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.prro.2022.02.003","volume":"12","author":"V Gondi","year":"2022","unstructured":"Gondi V et al (2022) Radiation therapy for brain metastases: an ASTRO clinical practice guideline. Pract Radiat Oncol 12(4):265\u2013282","journal-title":"Pract Radiat Oncol"},{"issue":"9","key":"4097_CR49","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s00066-025-02416-w","volume":"201","author":"C Grinzinger","year":"2025","unstructured":"Grinzinger C et al (2025) Effects of concurrent HER2-directed therapy on development of cerebral radionecrosis after stereotactic radiotherapy: a systematic review. Strahlenther Onkol 201(9):863\u2013873","journal-title":"Strahlenther Onkol"},{"issue":"4","key":"4097_CR50","first-page":"1059","volume":"52","author":"Y Lin","year":"2020","unstructured":"Lin Y et al (2020) Real-World data of Pyrotinib-Based therapy in metastatic HER2-Positive breast cancer: promising efficacy in Lapatinib-Treated patients and in brain metastasis. Cancer Res Treat 52(4):1059\u20131066","journal-title":"Cancer Res Treat"},{"issue":"7","key":"4097_CR51","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1056\/NEJMoa1914609","volume":"382","author":"RK Murthy","year":"2020","unstructured":"Murthy RK et al (2020) Tucatinib, Trastuzumab, and capecitabine for HER2-Positive metastatic breast cancer. N Engl J Med 382(7):597\u2013609","journal-title":"N Engl J Med"},{"issue":"2","key":"4097_CR52","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1001\/jamaoncol.2022.5610","volume":"9","author":"NU Lin","year":"2023","unstructured":"Lin NU et al (2023) Tucatinib vs Placebo, both in combination with trastuzumab and Capecitabine, for previously treated ERBB2 (HER2)-Positive metastatic breast cancer in patients with brain metastases: updated exploratory analysis of the HER2CLIMB randomized clinical trial. JAMA Oncol 9(2):197\u2013205","journal-title":"JAMA Oncol"},{"issue":"4","key":"4097_CR53","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1001\/jama.2016.9839","volume":"316","author":"PD Brown","year":"2016","unstructured":"Brown PD et al (2016) Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: A randomized clinical trial. JAMA 316(4):401\u2013409","journal-title":"JAMA"},{"issue":"23","key":"4097_CR54","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.22.00520","volume":"40","author":"N Ramakrishna","year":"2022","unstructured":"Ramakrishna N et al (2022) Management of advanced human epidermal growth factor receptor 2-Positive breast cancer and brain metastases: ASCO guideline update. J Clin Oncol 40(23):2636\u20132655","journal-title":"J Clin Oncol"}],"container-title":["Neurosurgical Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10143-025-04097-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10143-025-04097-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10143-025-04097-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T06:02:26Z","timestamp":1769839346000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10143-025-04097-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,31]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4097"],"URL":"https:\/\/doi.org\/10.1007\/s10143-025-04097-6","relation":{},"ISSN":["1437-2320"],"issn-type":[{"value":"1437-2320","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,31]]},"assertion":[{"value":"4 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}},{"value":"The authors declare no competing interests.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"182"}}